ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson''s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Latest shares articles
An unprecedented signal just triggered on the US Dollar
The US dollar just collapsed against the Taiwanese new dollar, with the pairing falling 8% in just a few days, crashing below this key support line and reaching its lowest level in over a year.
19 hours ago
Trading Gold’s short-term bull channel
Denial of Fed Chair Powell’s removal has meant a pullback off the highs, but what will it take to get gold prices to break out of its short-term bull channel?
07:23, 17 July 2025
Nasdaq 100: Trading US CPI
Futures up on Nvidia’s China sales resumption of AI chips, but the next test is US pricing data.
06:29, 15 July 2025
Cocoa price prediction: Third-party target
Read our cocoa price forecast for 2025 and beyond, with insights from third-party analysts and commodities market experts.
15:58, 14 July 2025
Ratings and Reviews
Ratings and Reviews
